These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 11355274)

  • 81. [Potential therapeutic approaches for prevention and treatment of diabetic nephropathy and neuropathy: evidences of cilostazol].
    Rosa MP; Baroni GV; Portal VL
    Arq Bras Endocrinol Metabol; 2007 Dec; 51(9):1528-32. PubMed ID: 18209897
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Pentoxifylline in the treatment of intermittent claudication of the lower limbs.
    Reich T; Cutler BC; Lee BY; Porter JM; Reichle FA; Scogin JT; Strandness DE
    Angiology; 1984 Jul; 35(7):389-95. PubMed ID: 6380347
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Application of adaptive design and decision making to a phase II trial of a phosphodiesterase inhibitor for the treatment of intermittent claudication.
    Lewis RJ; Connor JT; Teerlink JR; Murphy JR; Cooper LT; Hiatt WR; Brass EP
    Trials; 2011 May; 12():134. PubMed ID: 21612611
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Demonstration of the efficacy of ginkgo biloba special extract EGb 761 on intermittent claudication--a placebo-controlled, double-blind multicenter trial.
    Peters H; Kieser M; Hölscher U
    Vasa; 1998 May; 27(2):106-10. PubMed ID: 9612115
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Combined aspirin and cilostazol treatment is associated with reduced platelet aggregation and prevention of exercise-induced platelet activation.
    Cleanthis M; Bhattacharya V; Smout J; Ashour H; Stansby G
    Eur J Vasc Endovasc Surg; 2009 May; 37(5):604-10. PubMed ID: 19297212
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Cilostazol: a replacement for pentoxifylline?
    Shukla V
    Issues Emerg Health Technol; 1999 Jul; (7):1-4. PubMed ID: 11811214
    [No Abstract]   [Full Text] [Related]  

  • 87. Treatment with pharmacological agents in peripheral arterial disease patients does not result in biomechanical gait changes.
    Huisinga JM; Pipinos II; Stergiou N; Johanning JM
    J Appl Biomech; 2010 Aug; 26(3):341-8. PubMed ID: 20841626
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Clinical efficacy and safety of cilostazol: a critical review of the literature.
    Rogers KC; Oliphant CS; Finks SW
    Drugs; 2015 Mar; 75(4):377-95. PubMed ID: 25758742
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication (Br J Surg 2012; 99: 1630-1638).
    Roset PN
    Br J Surg; 2013 Dec; 100(13):1838. PubMed ID: 24227374
    [No Abstract]   [Full Text] [Related]  

  • 90. Authors' reply: systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication (Br J Surg 2012; 99: 1630-1638).
    Stevens JW; Simpson E; Harnan S; Squires H; Meng Y; Thomas S; Michaels J; Stansby G
    Br J Surg; 2013 Dec; 100(13):1838-9. PubMed ID: 24227373
    [No Abstract]   [Full Text] [Related]  

  • 91. Exercise and peripheral arterial disease.
    Kim DH
    Ann Intern Med; 2006 May; 144(9):699; author reply 699-700. PubMed ID: 16670144
    [No Abstract]   [Full Text] [Related]  

  • 92. Effects of OP-1206 alpha-CD on walking dysfunction in the rat neuropathic intermittent claudication model: comparison with nifedipine, ticlopidine and cilostazol.
    Nakai K; Takenobu Y; Takimizu H; Akimaru S; Maegawa H; Ito H; Marsala M; Katsube N
    Prostaglandins Other Lipid Mediat; 2003 Jul; 71(3-4):253-63. PubMed ID: 14518565
    [TBL] [Abstract][Full Text] [Related]  

  • 93. [Clinical studies in peripheral arterial occlusive disease: update from the aspects of a meta-narrative review].
    Melzer J; Saller R
    Forsch Komplementmed; 2013; 20 Suppl 2():17-21. PubMed ID: 23860108
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Pentoxifylline for intermittent claudication. A critical review.
    Ernst E
    Angiology; 1994 May; 45(5):339-45. PubMed ID: 8172380
    [TBL] [Abstract][Full Text] [Related]  

  • 95. A meta-analysis of randomized, double-blind, placebo-controlled studies of the effect of buflomedil on intermittent claudication.
    Walker GA; Mac Hannaford JC
    Fundam Clin Pharmacol; 1995; 9(4):387-94. PubMed ID: 8566940
    [TBL] [Abstract][Full Text] [Related]  

  • 96. European multicenter study on propionyl-L-carnitine in intermittent claudication.
    Brevetti G; Diehm C; Lambert D
    J Am Coll Cardiol; 1999 Nov; 34(5):1618-24. PubMed ID: 10551714
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Pharmacological management of intermittent claudication: a meta-analysis of randomised trials.
    Moher D; Pham B; Ausejo M; Saenz A; Hood S; Barber GG
    Drugs; 2000 May; 59(5):1057-70. PubMed ID: 10852639
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Multicenter double-blind study of ticlopidine in the treatment of intermittent claudication and the prevention of its complications.
    Arcan JC; Blanchard J; Boissel JP; Destors JM; Panak E
    Angiology; 1988 Sep; 39(9):802-11. PubMed ID: 3048155
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Cilostazol: a Review of Basic Mechanisms and Clinical Uses.
    Kherallah RY; Khawaja M; Olson M; Angiolillo D; Birnbaum Y
    Cardiovasc Drugs Ther; 2022 Aug; 36(4):777-792. PubMed ID: 33860901
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Inhibition of adenosine uptake and augmentation of ischemia-induced increase of interstitial adenosine by cilostazol, an agent to treat intermittent claudication.
    Liu Y; Fong M; Cone J; Wang S; Yoshitake M; Kambayashi J
    J Cardiovasc Pharmacol; 2000 Sep; 36(3):351-60. PubMed ID: 10975593
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.